DIRS.INFO The most relevant business & tech news

☆ Bernstein picks recession-beating global stocks for ‘value, growth and quality’
▼ + stars: | 2023-08-03 | by ( Lucy Handley | ) www.cnbc.com time to read: +2 min

Investment bank Bernstein picked a raft of Chinese and Indian stocks in sectors including tech, pharma and IT, naming them on a list of "opportunities for value, growth and quality." "We believe that it is time to increase risk exposure in China by adding more high volatility stocks," the analysts wrote. "GPT can accelerate development of its business and give the company the tailwinds to reshape its strategy," the analysts wrote. Indian stock picks Indian drug company Sun Pharma is also on Bernstein's list of outperform-rated stocks. In India … they have outperformed the market," the analysts wrote, and they also praised Sun's specialty drug portfolio in the U.S.

Persons: Bernstein, Rupal Agarwal, India … Organizations: pharma, " Pharma, Wuxi, Baidu, Sun Pharma, U.S, Infosys, Reliance Industries, New Locations: Asia, China, Wuxi, India, Bangalore, New Commerce

☆ Indian shares open higher as SVB acquisition hopes aid sentiment
▼ + stars: | 2023-03-27 | by ( ) www.reuters.com time to read: +1 min

BENGALURU, March 27 (Reuters) - Indian shares opened higher on Monday after reports of advanced talks for the acquisition of collapsed Silicon Valley Bank brought relief to markets, although fears of contagion in the global banking system lingered. Eight of the 13 major sectoral indexes advanced, with the heavyweight financials index (.NIFTYFIN) adding 0.3%. While reports of a potential acquisition of Silicon Valley Bank by First Citizens BancShares Inc calmed nerves, concerns over credit crunch persisted, putting authorities on high alert over the fallout from recent banking turmoil. Among individual Indian stocks, shares of Phoenix Mills (PHOE.NS) jumped nearly 6% after global brokerage firm Morgan Stanley initiated coverage on the stock with an "overweight" recommendation. ($1 = 82.1970 Indian rupees)Reporting by Bharath Rajeswaran in Bengaluru; editing by Eileen SorengOur Standards: The Thomson Reuters Trust Principles.

☆ Indian shares open lower on Fed rate hike fears, China COVID-19 woes
▼ + stars: | 2022-12-23 | by ( ) www.reuters.com time to read: +1 min

BENGALURU, Dec 23 (Reuters) - Indian shares opened lower in broad-based declines on Friday after robust U.S. economic data revived concerns over higher interest rates, while a surge in COVID-19 infections in China also dampened risk appetite. The Nifty 50 index (.NSEI) was down 0.78% at 17,988 as of 9:30 a.m. IST, dropping below the 18,000 mark for the first time since Nov. 10. Reuters GraphicsChina is expecting a peak in COVID-19 infections within a week, a health official said, sparking concerns across the world. The one exception was the pharma index, <.NIPHARM>, which rose 1.36% on news that India is ready to step up exports of fever medicines to China. Asian markets also declined after the slide in U.S. shares, with the MSCI Asia ex Japan (.MIAPJ0000PUS) falling 0.94%.

☆ BioNTech ships COVID shots to China for use by Germans
▼ + stars: | 2022-12-22 | by ( ) www.reuters.com time to read: +3 min

BioNTech said it is working with Shanghai Fosun Pharmaceutical (600196.SS) to deliver the shots to greater China, with availability expected in Beijing, Shanghai, Guangzhou, Shenyang and Chengdu. China would need to approve expanding access beyond the about 20,000 German nationals, the source said on Wednesday. "Most of Chinese here got the BioNTech vaccine, the vaccine that was first available. SinoVac vaccine was not available in Europe," a first-generation Chinese expatriate who has lived in Europe for more than a decade told Reuters. The expatriate, who asked to remain anonymous to protect their family in China, said that the government there might only make BioNTech shots available to Chinese nationals if it came to the worst-case scenario.

☆ Indian shares set to rise on China recovery hopes
▼ + stars: | 2022-12-19 | by ( ) www.reuters.com time to read: +2 min

BENGALURU, Dec 19 (Reuters) - Indian shares are set to open higher on Monday on hopes of demand recovery in China, even as concerns of global recession linger. Asian markets rebounded after a mixed start on hopes of demand recovery in China, with the MSCI Asia ex Japan (.MIAPJ0000PUS) rising 0.3%. Reports say that China planned to increase flights to encourage the recovery of its air transport market. Foreign institutional investors sold 19.75 billion rupees ($238.80 million) worth of equities on a net basis on Friday, while domestic investors bought 15.42 billion rupees ($186.44 million) of shares, as per provisional NSE data. ** Dilip Buildcon (DIBL.NS): Co gets order worth 16.47 billion rupees.

☆ India's Sun Pharma says plant listed under U.S. FDA import alert
▼ + stars: | 2022-12-08 | by ( ) www.reuters.com time to read: +1 min

BENGALURU, Dec 8 (Reuters) - The U.S. Food and Drug Administration (FDA) had listed Indian drugmaker Sun Pharmaceutical Industries Ltd's (SUN.NS) facility in the western Indian state of Gujarat under an import alert, the company said on Thursday, sending its shares down 3.6%. The import alert means all future shipments of products made at the Halol plant can be refused admission to the U.S. market until the facility becomes compliant with the FDA's Current Good Manufacturing Practice standards, Sun Pharma said in a statement. The FDA has excluded 14 products from the import alert, subject to certain conditions. It was not immediately clear what the conditions are and what remedial action the FDA had asked the company to take. Reporting by Navamya Ganesh Acharya in Bengaluru; Editing by Subhranshu Sahu and Savio D'SouzaOur Standards: The Thomson Reuters Trust Principles.

☆ INDIA STOCKS Indian shares set for muted opening; Fed meet in focus
▼ + stars: | 2022-11-02 | by ( ) www.reuters.com time to read: +3 min

** Adani Ports and Special Economic Zone APSE.NS, India's largest private operator of ports, reported a 69% surge in quarterly profit on Tuesday, driven by strong cargo volumes. ** Sun Pharmaceutical Industries Ltd (SUN.NS) on Tuesday reported a surprise 10.5% rise in second quarter profit led by a surge in sales of specialty drugs. ** IT services provider Tech Mahindra (TEML.NS)reported better-than-expected quarterly profit and revenue on Tuesday, helped by strong demand and the company also declared a special dividend. ** Kansai Nerolac Paints Ltd (KANE.NS)reported a weaker-than-expected rise in second quarter profit on Tuesday, hit by higher input costs and a demand squeeze due to unseasonal rains. ** Voltas Ltd (VOLT.NS)posted a loss for the second quarter on Tuesday, dented by higher expenses and a one-off expense related to a contract termination.

☆ INDIA STOCKS Indian shares seen opening higher, Fed in focus
▼ + stars: | 2022-11-01 | by ( ) www.reuters.com time to read: +3 min

BENGALURU, Nov 1 (Reuters) - Indian shares may kick off November trading on a higher note on Tuesday, after rising for three straight sessions, tracking gains in broader Asia as investors turn focus to the U.S. Federal Reserve policy meeting this week. India's NSE stock futures, listed on the Singapore exchange , were 0.61% higher as of 0203 GMT. Investors this week will be looking for the outcome of the Fed policy meeting and the outlook on future rate hikes path. The Fed is widely expected to raise interest rates by 75 basis points on Wednesday at the conclusion of its two-day policy meeting. ($1 = 82.7910 Indian rupees)Reporting by Rama Venkat in Bengaluru; Editing by Dhanya Ann ThoppilOur Standards: The Thomson Reuters Trust Principles.

☆ WADA outlaws tramadol use from 2024, maintains cannabis ban
▼ + stars: | 2022-09-23 | by ( ) www.reuters.com time to read: +2 min

A pharmacist holds a bottle of traMADOL Hydrochloride made by Sun Pharma at a pharmacy in Provo, Utah, U.S., May 9, 2019. REUTERS/George Frey/FilesSYDNEY, Sept 23 (Reuters) - The World Anti-Doping Agency will add the painkiller tramadol to the list of banned substances for athletes in competition from 2024 and has maintained its ban on cannabis after a review. Register now for FREE unlimited access to Reuters.com Register"Research studies funded by WADA have also confirmed the potential for tramadol to enhance physical performance." WADA said the delay in introducing the ban until 2024 was to allow the communication of the implications of it to athletes, their entourages and medical staff. After requests from some "stakeholders", however, WADA agreed to review the cannabis ban but decided on Friday to maintain it because the use of the drug "violated the spirit of sport".

☆ Вакцина как бизнес. Сколько зарабатывают на них фармкомпании
▼ + stars: | 2021-07-08 | by ( Mld Media Srl | Степанов Георгий | ) noi.md time to read: +5 min

PfizerКомпания Pfizer заявила, что её вакцина принесла $3,5 млрд выручки за первые три месяца 2021 года. Johnson & Johnson и AstraZenecaАмериканская компания Johnson & Johnson и англо-шведская AstraZeneca пообещали продавать свои вакцины на некоммерческой основе во время пандемии. Вакцина AstraZeneca от COVID-19 принесла создателям в первом квартале 2021 года $275 млн выручки. Johnson & Johnson сообщила, что её вакцина за первые три месяца года принесла $100 млн выручки. Kelly Scientific указывает сумму $59 млрд в 2021 году и снижение её до $47 млрд к 2026 году.

Persons: — BioNTech, Pfizer BioNTech, Johnson, Johnson AstraZeneca Johnson, Sinovac, Morningstar, Kelly, —, Альберт Бурла, Алекс Горски, Джошуа Коэн, Джон ЛаМатинна, Карен Андерсен Organizations: Pfizer, BioNTech, Pfizer Fosun Pharma, Pfizer Pfizer, Johnson, AstraZeneca, AstraZeneca COVID, Guardian, Moderna Johnson, Forbes . Forbes, — Pfizer, Спутник, Всемирная организация здравоохранения (ВОЗ), Африканский союз, Альпари, & Locations: vc.ru, COVID, BioNTech Moderna, вакцинахЕС, США, Евросоюз, Бразилия, Чили, Сингапур, Малайзией, Филиппинами, Турция, Индонезия, Китай, Венгрия, Словакия, ЕС, Россия

☆ В Мумбаи из-за нехватки вакцины закрыты все прививочные центры
▼ + stars: | 2021-04-30 | by ( Mld Media Srl | ) noi.md time to read: +2 min

В Мумбаи, крупнейшем городе Индии, на три дня приостановили прививки от коронавируса из-за нехватки вакцин. В Индии — резкий всплеск заболеваемости, каждый день выявляют сотни тысяч новых инфицированных, число смертей обновляет рекорды. Для сравнения: впервые этой цифры в статистике с начала эпидемии Индия достигла за шесть месяцев — в три раза более долгий срок. 12 апреля Индия одобрила экстренное применение российской вакцины «Спутник V», она стала третьей разрешенной в стране вакциной. Первую партию «Спутника V» Индия получит 1 мая.

Organizations: Reuters, Pharma, человекС, Российский фонд прямых инвестиций, Спутник Locations: Мумбаи, Индия, Россия, США

☆ Hong Kong a suspendat vaccinarea cu Pfizer/BioNTech. Au fost semnalate probleme la capacele dozelor
▼ + stars: | 2021-03-24 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

Hong Kong a suspendat miercuri utilizarea vaccinului Pfizer/BioNTech după ce distribuitorul a informat autorităţile că un lot are capacele dozelor defecte, relatează Mediafax, citat de digi24.ro. Guvernul a luat decizia de a suspenda din motive de precauţie vaccinarea cu toate loturile Pfizer cât timp este investigată problema. Toate centrele comunitare din Hong Kong care administrează vaccinul Pfizer au suspendat temporar vaccinările şi rezidenţii care au făcut deja programări pentru miercuri nu trebuie să meargă la centre, a spus guvernul. Suspendarea vaccinului Pfizer înseamnă că singurul vaccin oferit în prezent rezidenţilor este vaccinul Sinovac din China. 403.000 de persoane au primit vaccinuri în metropolă, dintre care 150.200 au primit Pfizer, comparativ cu 252.800 care au luat primit Sinovac.

Organizations: Hong, Mediafax Locations: Hong Kong, China

☆ China solicită aprobare pentru primul său vaccin anti-Covid, cu eficiență mai mică decât Pfizer sau Moderna
▼ + stars: | 2020-12-30 | by ( ) www.jurnal.md time to read: +2 min

Sinopharm este prima companie farmaceutică de stat chineză care a comunicat cifre privind eficacitatea unui vaccin în pregătire, notează AFP, citată de Agerpres. Într-un comunicat, Sinopharm a menţionat o eficacitate de 79,43% pentru acest vaccin produs de laboratorul CNBG din Beijing, procent inferior vaccinurilor laboratoarelor Pfizer-BioNTech (95%) şi Moderna (94,1%). Compania britanică Astrazeneca, asociată Universităţii Oxford, a indicat la rândul său o rată de eficacitate de 70%, dar care ar putea atinge 100% după două doze. China, pe al cărei teritoriu a fost semnalată în urmă cu un an apariţia coronavirusului, are în curs de testare clinică faza 3 cinci vaccinuri. Sinopharm a depus o cerere de omologare a acestui prim vaccin către autorităţile din China, scrie Reuters.

Persons: Sinopharm, Reuters, Liu Jingzhen Organizations: Universităţii, Agerpres Locations: Sinopharm, Beijing, Universităţii Oxford, China, Wuhan, Chinei, Fosun

☆ Un medicament pentru COVID se va fabrica în România
▼ + stars: | 2020-12-19 | by ( ) www.jurnal.md time to read: +2 min

Terapia Cluj, cel mai mare producător local de medicamente, a anunţat că din aprilie 2021 începe producţia în România de favipiravir, un medicament antiviral folosit în tratarea simptomelor medii şi uşoare de COVID. FluGuard (favipiravir) este un medicament eliberat pe bază de prescripţie medicală, produs de Sun Pharma, grup din care face parte producătorul local Terapia. Producătorul care va fabrica dozele în sistem externalizat pentru Terapia va primi fie materia primă, fie tabletele pentru a se ocupa de ambalarea acestora. Până acum, Terapia a adus 770.000 de tablete de favipiravir în România, în mai multe tranşe, ultimul lot urmând să ajungă în 20 decembrie. Această cantitate va acoperi tratamentul pentru aproximativ 1.000 de pacienţi şi va fi donată unităţilor medicale care tratează pacienţi cu COVID-19.

Persons: Damian Organizations: Sun Pharma, Mediafax Locations: Cluj, România, FluGuard, SUA

Search resuls for: "Sun Pharma"

14 mentions found